Retatrutide vs GLP-1: Triple Agonist vs Single Agonist Compared
Retatrutide is a triple agonist — GLP-1 + GIP + glucagon. How it compares to standard GLP-1 receptor agonists like semaglutide and tirzepatide on mechanism, weight loss and timeline.
The next generation of obesity pharmacology doesn't just bind the GLP-1 receptor — it binds three receptors at once. Retatrutide (Eli Lilly, in Phase 3) is a triple agonist of GLP-1, GIP and glucagon, and its Phase 2 weight-loss numbers exceeded every approved GLP-1 drug.
This is the head-to-head: retatrutide vs the currently-approved GLP-1 receptor agonists, on mechanism, efficacy, side-effect profile and status.
For the deep retatrutide guide, see our Retatrutide pillar.
The mechanism difference
Standard GLP-1 receptor agonists
Bind one receptor — the GLP-1 receptor. Effects:
- Glucose-dependent insulin release
- Glucagon suppression
- Slowed gastric emptying
- Central appetite suppression
Examples: semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), dulaglutide (Trulicity), exenatide.
Dual agonists (GLP-1 + GIP)
Add GIP receptor activation, which amplifies the insulin response and adds adipose-tissue effects. The current state of the art.
Example: tirzepatide (Mounjaro, Zepbound).
Triple agonists (GLP-1 + GIP + glucagon)
Adds glucagon receptor activation — which counterintuitively increases weight loss by raising energy expenditure. This is the retatrutide approach.
Glucagon is the hormone that opposes insulin (raises blood sugar by prompting the liver to release stored glucose), but in the right combination with GLP-1 and GIP activation it has different downstream effects:
- Raises basal metabolic rate
- Increases fat oxidation in the liver
- Reduces hepatic fat (relevant for MASH)
The combination of three pathways produces effects beyond what dual or single agonists can achieve.
How retatrutide compares on weight loss
| Drug | Class | Trial top dose | Average weight loss | Trial length |
|---|---|---|---|---|
| Retatrutide 12 mg | Triple GLP-1/GIP/glucagon | 12 mg/week | ~24% | 48 weeks (Phase 2) |
| Zepbound (tirzepatide) 15 mg | Dual GLP-1/GIP | 15 mg/week | ~21% | 72 weeks |
| Wegovy (semaglutide) 2.4 mg | Single GLP-1 | 2.4 mg/week | ~15% | 68 weeks |
| Saxenda (liraglutide) 3.0 mg | Single GLP-1 | 3.0 mg/day | ~8% | 56 weeks |
Retatrutide's Phase 2 results came at 48 weeks. Phase 3 trials (the TRIUMPH program) are reading out through 2026 with longer duration; final efficacy numbers may shift.
The headline: retatrutide produced higher average weight loss in 48 weeks than tirzepatide did in 72 weeks. That's a meaningful step.
Side-effect profile
The class GI profile carries through. Each additional receptor target adds some unique signals.
| Side effect | Single GLP-1 | Dual GLP-1/GIP | Triple |
|---|---|---|---|
| Nausea | Common | Common | Common |
| Vomiting | Common | Common | Common |
| Diarrhea / constipation | Common | Common | Common |
| GI burden during titration | Significant | Significant | Significant |
| Dysesthesia (tingling, altered sensation) | Rare | Rare | Documented in retatrutide trials (~20% at 12 mg) |
| Pancreatitis | Rare | Rare | Rare |
Dysesthesia is a notable retatrutide-specific signal that appeared across Phase 2 dose-response data — believed to relate to the glucagon receptor activation. It's typically dose-related.
Approval status
| Drug | Status |
|---|---|
| Semaglutide | FDA-approved for T2D (Ozempic, Rybelsus), weight management (Wegovy, Wegovy oral), CV risk reduction, MASH |
| Tirzepatide | FDA-approved for T2D (Mounjaro), weight management + OSA (Zepbound) |
| Liraglutide | FDA-approved for T2D (Victoza), weight management (Saxenda) |
| Retatrutide | Phase 3 (TRIUMPH program); NDA expected late 2026; approval projected 2027–2028 |
Retatrutide isn't legally available outside clinical trials in 2026. Anything labeled "retatrutide" sold to consumers is a research peptide — not a pharmaceutical product. See our Retatrutide guide for the legality and clinical-trial enrollment options.
Why glucagon agonism counterintuitively helps weight loss
The naïve expectation: glucagon raises blood sugar by triggering hepatic glucose output, so adding glucagon agonism to a diabetes drug seems wrong.
What the data shows in retatrutide's case:
- Combined with GLP-1 and GIP receptor activation, the insulin response is so amplified that net blood sugar still falls
- The glucagon arm specifically increases energy expenditure — basal metabolic rate rises modestly
- Hepatic fat oxidation increases — relevant for fatty liver disease
So you get GLP-1's appetite suppression + GIP's amplified insulin response + glucagon's metabolic effect on energy expenditure, all in one molecule. Net: more weight loss than any single mechanism alone.
Pipeline alongside retatrutide
Other multi-receptor drugs in development:
- Survodutide (Boehringer Ingelheim) — dual GLP-1/glucagon agonist; Phase 3 for obesity and MASH
- Pemvidutide (Altimmune) — dual GLP-1/glucagon; Phase 2/3
- CagriSema (Novo Nordisk) — semaglutide + cagrilintide (amylin analog) combination; Phase 3
- Mazdutide (Lilly / Innovent) — dual GLP-1/glucagon, Asia-focused development
Should you wait for retatrutide?
For someone considering starting a GLP-1 now:
- Realistic timeline: approval likely late 2027 to early 2028, followed by months of access ramp-up
- Practical effect: for someone with a clinical indication today, waiting 1-2+ years for a drug that may produce ~3-5 percentage points more average weight loss isn't necessarily worth it
- The right approach: treat the condition you have today with an approved drug; switch to a better option later if/when it becomes available
For people without obesity-related health issues, waiting is fine — research the landscape and make decisions when retatrutide is on the market.
FAQ
Is retatrutide a GLP-1? Yes — retatrutide is a GLP-1 receptor agonist, plus a GIP and glucagon receptor agonist. Triple agonist.
Is retatrutide FDA-approved? No. It's in Phase 3 clinical trials as of 2026. Approval projected for 2027–2028.
How much weight do people lose on retatrutide? Phase 2 average at 12 mg/week was ~24% body weight at 48 weeks. Final Phase 3 figures will appear as TRIUMPH reads out.
Can I get retatrutide right now? Only through clinical-trial enrollment. Anything sold commercially as "retatrutide" is a research peptide outside the legal prescription system.
Is retatrutide better than tirzepatide? On Phase 2 weight-loss data, yes — by a meaningful margin. Side-effect profile is broadly similar with one new signal (dysesthesia).
Why does retatrutide have a glucagon receptor agonist on it if glucagon raises blood sugar? Because the combination with GLP-1 and GIP activation produces an overall insulin-dominant effect, while glucagon adds energy expenditure and hepatic fat oxidation benefits.
This article is for educational purposes only and is not medical advice. Retatrutide is investigational and not FDA-approved. Discuss treatment options with a qualified healthcare professional.